Charles Schwab
FATE icon

Charles Schwab’s Fate Therapeutics FATE Stock Holding History

Charles Schwab’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
610,949
-145,324
-19% -$269K ﹤0.01% 2852
2026
Q1 		$908K Sell
756,273
-28,355
-4% -$34.5K ﹤0.01% 2930
2025
Q4 		$771K Sell
784,628
-1,293
-0.2% -$1.55K ﹤0.01% 3014
2025
Q3 		$990K Buy
785,921
+52,010
+7% +$56.1K ﹤0.01% 2959
2025
Q2 		$822K Buy
733,911
+30,086
+4% +$35K ﹤0.01% 2963
2025
Q1 		$556K Sell
703,825
-66,455
-9% -$81.4K ﹤0.01% 3043
2024
Q4 		$1.27M Buy
770,280
+6,472
+0.8% +$16.3K ﹤0.01% 2827
2024
Q3 		$2.67M Sell
763,808
-115,567
-13% -$450K ﹤0.01% 2616
2024
Q2 		$2.88M Sell
879,375
-76,956
-8% -$337K ﹤0.01% 2579
2024
Q1 		$7.02M Sell
956,331
-26,688
-3% -$165K ﹤0.01% 2163
2023
Q4 		$3.68M Buy
983,019
+96,304
+11% +$227K ﹤0.01% 2436
2023
Q3 		$1.88M Buy
886,715
+249,932
+39% +$828K ﹤0.01% 2617
2023
Q2 		$3.03M Buy
636,783
+17,948
+3% +$99.1K ﹤0.01% 2421
2023
Q1 		$3.53M Buy
618,835
+4,202
+0.7% +$25.4K ﹤0.01% 2354
2022
Q4 		$6.2M Buy
614,633
+13,155
+2% +$247K ﹤0.01% 2108
2022
Q3 		$13.5M Sell
601,478
-220,505
-27% -$6.37M ﹤0.01% 1653
2022
Q2 		$20.4M Buy
821,983
+6,601
+0.8% +$182K 0.01% 1402
2022
Q1 		$31.6M Buy
815,382
+20,674
+3% +$801K 0.01% 1184
2021
Q4 		$46.5M Buy
794,708
+17,381
+2% +$985K 0.01% 947
2021
Q3 		$46.1M Buy
777,327
+194,189
+33% +$15.2M 0.02% 936
2021
Q2 		$50.6M Buy
583,138
+18,796
+3% +$1.51M 0.02% 861
2021
Q1 		$46.5M Buy
564,342
+83,914
+17% +$8.04M 0.02% 883
2020
Q4 		$43.7M Buy
480,428
+6,341
+1% +$394K 0.02% 850
2020
Q3 		$18.9M Buy
474,087
+29,815
+7% +$1.04M 0.01% 1240
2020
Q2 		$15.2M Buy
444,272
+58,866
+15% +$1.75M 0.01% 1361
2020
Q1 		$8.56M Buy
385,406
+5,194
+1% +$131K 0.01% 1538
2019
Q4 		$7.44M Buy
380,212
+38,803
+11% +$616K ﹤0.01% 1817
2019
Q3 		$5.3M Buy
341,409
+210,836
+161% +$4.04M ﹤0.01% 1929
2019
Q2 		$2.65M Sell
130,573
-13,759
-10% -$248K ﹤0.01% 2274
2019
Q1 		$2.54M Buy
144,332
+5,794
+4% +$91.5K ﹤0.01% 2284
2018
Q4 		$1.78M Buy
138,538
+27,578
+25% +$385K ﹤0.01% 2373
2018
Q3 		$1.81M Buy
110,960
+5,660
+5% +$66.9K ﹤0.01% 2459
2018
Q2 		$1.2M Buy
105,300
+7,800
+8% +$85.9K ﹤0.01% 2533
2018
Q1 		$952K Buy
97,500
+31,500
+48% +$302K ﹤0.01% 2532
2017
Q4 		$404K Hold
66,000
– – ﹤0.01% 2781
2017
Q3 		$262K Hold
66,000
– – ﹤0.01% 2926
2017
Q2 		$214K Buy
+66,000
New +$253K ﹤0.01% 3011

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab's FATE Position: Q2 2026 in Review

Charles Schwab reduced its Fate Therapeutics (FATE) stake by 19% in Q2 2026, selling an estimated $269K and leaving 610,949 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

Charles Schwab first reported a position in FATE in Q2 2017 and has held it in 37 quarters since. The position peaked at $50.6M in Q2 2021. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Charles Schwab held 610,949 shares of Fate Therapeutics worth $1.65M as of Q2 2026.
  • Charles Schwab sold 145,324 Fate Therapeutics shares in Q2 2026, an estimated $269K.
  • Fate Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2852 holding.
  • Charles Schwab first reported a position in Fate Therapeutics in Q2 2017 and has held it in 37 quarters since.
  • Charles Schwab's Fate Therapeutics position peaked at $50.6M in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.